Last reviewed · How we verify
Chewing Ticagrelor LD
Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.
Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events. Used for Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events, Secondary prevention of atherothrombotic events in patients with acute myocardial infarction.
At a glance
| Generic name | Chewing Ticagrelor LD |
|---|---|
| Sponsor | Sheba Medical Center |
| Drug class | P2Y12 receptor antagonist (antiplatelet agent) |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, blocking platelet activation and aggregation. This antiplatelet effect reduces the formation of blood clots and is used to prevent cardiovascular events in acute coronary syndromes and other thrombotic conditions. The chewing formulation (low-dose loading dose) allows for rapid onset of action in acute settings.
Approved indications
- Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events
- Secondary prevention of atherothrombotic events in patients with acute myocardial infarction
Common side effects
- Bleeding
- Bradycardia
- Dyspnea
- Ventricular pauses
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |